Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury
Oragenics Completes Approximately $16.5 Million Offering
Seeking Alpha / 13 hours ago 2 Views
Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury
Comments